key: cord-0716069-3u0e5w6b
authors: Kyaw, Htin; Shajahan, Shehanaz; Gulati, Amit; Synn, Shwe; Khurana, Sakshi; Nazar, Nijas; Shrestha, Suvash; Kerstein, Joshua
title: COVID-19 mRNA Vaccine-Associated Myocarditis
date: 2022-01-07
journal: Cureus
DOI: 10.7759/cureus.21009
sha: 269356487117418914ddc97b3d9d350ae8b4a870
doc_id: 716069
cord_uid: 3u0e5w6b

Coronavirus disease 2019 (COVID-19) has been reported to cause cardiovascular complications including myocarditis, pericardial effusion, pericarditis, and arrhythmias. With the introduction of the vaccine, there have been reports of myocarditis possibly associated with the mRNA COVID-19 vaccine. We report a case of cardiac involvement following the second dose of Pfizer-BioNTech COVID-19 vaccine in a young male. A healthy 24-year-old male presented to the emergency department with complaints of non-radiating mid-sternal chest pain and pressure. He noticed his symptoms started six hours after he received the second dose of Pfizer COVID vaccine. Laboratory tests revealed elevated cardiac troponin I-CtNI levels. Computed tomography angiography of the chest did not show evidence of pulmonary embolism. Given his presentation of acute chest pain associated with elevated troponin levels, a coronary angiogram was performed which revealed normal coronary arteries. He was subsequently treated for acute peri-myocarditis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and beta-blockers for tachycardia and the prevention of arrhythmia. Although rare, clinicians should be aware of the risk for myocarditis and pericarditis, which should be considered in individuals presenting with chest pain within a week after vaccination, especially in the younger population. Although the long-term risk in these patients is uncertain, early diagnosis and treatment are key to minimizing complications.

Cardiac injury has been reported as a potential complication of coronavirus disease 2019 (COVID-19) [1, 2] . Among cardiovascular complications, COVID-19 can be associated with myocarditis, pericardial effusion, pericarditis, and malignant arrhythmias [3] . The development of a vaccine against COVID-19 has been a big step in the fight against the pandemic. A two-dose regimen of BNT162b2 mRNA COVID-19 vaccine conferred 95% protection against COVID-19 in people of age 16 years or older [4] . With the introduction of the vaccine, there have been reports of myocarditis possibly associated with the mRNA COVID-19 vaccine [5] . However, these are extremely rare and according to the US Centers for Disease Control and Prevention, the rate of myocarditis/pericarditis is around 12.6 cases per million doses of second-dose mRNA vaccine among individuals of 12-39 years of age. Patients usually presented two to three days after the second dose of mRNA vaccination with chest pain, some preceded with fever and myalgia one day after vaccination. We report a case of cardiac involvement following the second dose of Pfizer-BioNTech COVID-19 vaccine in a young male.

A healthy 24-year-old male presented to the emergency department with complaints of non-radiating midsternal chest pain and pressure. His pain was worse on deep inspiration and lying down and improved on leaning forward. He also felt palpitations, shortness of breath, myalgias, and chills along with the pain. He noticed his symptoms started six hours after he received the second dose of Pfizer COVID vaccine. Myalgia and chills had since resolved but chest pain and pressure persisted. He denied fever, skin rash, trauma, unilateral leg pain or swelling, history of deep vein thrombosis/pulmonary embolism or hormonal use. He also denied a history of any high-risk conditions such as Marfan's syndrome, connective tissue disorder, and history of aortic surgery or aneurysm. He also did not report any prior COVID-19 infection. He had no known drug allergies and denied smoking or recreational drug use.

On examination, he appeared anxious. His temperature was 98.5°F, blood pressure was 130/85 mm Hg, heart rate was 120 beats/minute (bpm), and respiratory rate was 18 breaths/minute with oxygen saturation of 98% at room air. The remainder of the physical examination was unremarkable. Laboratory tests including complete blood count, comprehensive metabolic panel, lipid panel, thyroid function test, hemoglobin A1c were within normal limits. Nasopharyngeal swab for common respiratory viral pathogens including severe acute respiratory syndrome coronavirus 2 reverse transcription-polymerase chain reaction (SARS-CoV-2 RT-PCR) was negative. The B-type natriuretic peptide was 79 pg/ml (reference range: <100 pg/ml). Cardiac troponin I-CtNI on admission was 0.04 ng/ml, which then increased to 0.2 ng/ml and a peak of 8.45 ng/ml 10 hours after the initial troponin levels (reference range: 0.00-0.04 ng/ml). The chest x-ray on admission showed no radiographic evidence of active disease. Computed tomography angiography of the chest did not show evidence of pulmonary embolism. The electrocardiogram (ECG) on admission revealed sinus tachycardia with a heart rate of 120 bpm without any ST-segment change. The transthoracic echocardiogram on admission revealed normal left and right ventricular systolic function with a left ventricular ejection fraction of 55%. There was no hemodynamically significant valvular dysfunction.

Given his presentation of acute chest pain associated with elevated troponin levels, a coronary angiogram was performed which revealed normal coronary arteries (Figures 1-3) . He was subsequently treated for acute peri-myocarditis with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs), and beta-blockers for tachycardia and prevention of arrhythmia. His chest pain resolved the following day and was discharged home. 

While COVID-19 was initially thought to be a predominantly respiratory illness, as the pandemic progressed, it became apparent that there were cardiovascular involvement and thromboembolic complications [1, 6] . COVID-19 is also known to affect the vasculature resulting in myocardial injury [6] . Interestingly, there were reports of myocarditis after the COVID vaccine as well. Most cases manifested within a week after the second dose in young men [7] .

The mechanism of vaccine-induced myocarditis is not known but may be related to the active component of the vaccine, the mRNA sequence that codes for the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or to the immune response that follows vaccination [8] . Diagnostic evaluation including laboratory biomarkers, ECG, echocardiography, and MRI performed in patients presenting with chest pain after COVID vaccination showed a higher prevalence of vaccine-associated chest pain among males compared to females [8] .

The patient in our clinical scenario presented with typical pleuritic chest pain associated with myalgia and chills. He was otherwise healthy with no history of high-risk conditions. Laboratory tests were notable for elevated troponin with a peak of 8.45 ng/ml. There was no other cause identified for his symptoms other than a recent vaccination with the Pfizer COVID-19 vaccine. With this presentation, this patient would be classified as a probable case of acute myocarditis according to the CDC working case definitions for acute myocarditis and acute pericarditis.

CDC advocates myocarditis screening for patients who develop shortness of breath, chest pain, or palpitations within seven days of receiving the mRNA COVID-19 vaccine [5] . CDC is actively investigating reports of people developing myocarditis after receiving an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna). According to a survey conducted by CDC on a total of 247 individuals, 52% of patients reported no symptoms within the prior two weeks at a three-month follow-up of myocarditis after COVID-19 vaccination. Most of these people fully recovered, but the information is not yet available about potential long-term effects. Understanding the long-term health effects is critically important to explaining the risks and benefits of COVID-19 vaccination to the public and informing clinical guidance.

This case scenario confirms the possibility of COVID-19 vaccine-associated myocardial injury in younger males. In this case, the symptoms of the patient improved rapidly with treatment including colchicine, NSAIDs, and beta-blockers. Although rare, clinicians should be aware of the risk for myocarditis and pericarditis, which should be considered in individuals presenting with chest pain within a week after vaccination, especially in the younger population. Although the long-term risk in these patients is uncertain, early diagnosis and treatment are key to minimizing complications. Further studies need to be conducted to determine the incidence and prognosis of cardiac injury and to provide guidance on diagnosis and management of myocarditis following COVID-19 vaccination.

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

The impact of 2019 novel coronavirus on heart injury: a systematic review and meta-analysis

Covid-19 and the cardiovascular system: a comprehensive review

COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?

COVID-19 VaST work group report

Clinical considerations: myocarditis and pericarditis after receipt of mRNA COVID-19 vaccines among adolescents and young adults

COVID-19 and cardiovascular disease

Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel

Myocarditis with COVID-19 mRNA vaccines